Can Comprehensive Geriatric Assessment Predict Tolerance of Radiotherapy for Localized Prostate Cancer in Men Aged 75 Years or Older?
comprehensive geriatric assessment
geriatric rating scales
prostate cancer
quality of life
radiotherapy
toxicity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Mar 2020
09 Mar 2020
Historique:
received:
31
01
2020
revised:
02
03
2020
accepted:
03
03
2020
entrez:
19
3
2020
pubmed:
19
3
2020
medline:
19
3
2020
Statut:
epublish
Résumé
Curative radiotherapy for prostate cancer is common in the elderly. However, concerns about potential toxicity have inhibited access to radiotherapy for this population, for whom preserving quality of life (QoL) is crucial. The primary endpoint was to identify predictors of impaired QoL in men aged 75 years or older treated with curative intent radiotherapy with or without androgen deprivation therapy (ADT) for localized prostate cancer. We prospectively performed comprehensive geriatric assessment (CGA) and administered QoL questionnaires to 208 elderly (>75 years) patients prior to, plus two and six months after, radiotherapy (NCT02876237). The median age of the patients was 77 years (range 75-89). At the start of the study, comorbidities were highlighted in 65% of patients: 23% were depressed, 23% had cognitive impairment, and 16% had reduced independence. At six months, 9% of patients had a consistently decreased QoL (>20 points), and a further 16% had a more moderate reduction (10 to 20 points) in QoL. None of the parameters studied (tumor characteristic, treatment, or oncogeriatric parameters) were predictive of a reduced QoL following radiotherapy. Though co-existing geriatric impairment was common, QoL was maintained for 75% of patients six months after radiotherapy. CGA was poorly predictive of tolerance of prostatic radiotherapy. Geriatric assessments dedicated to quality of life following radiotherapy need to be developed.
Identifiants
pubmed: 32182949
pii: cancers12030635
doi: 10.3390/cancers12030635
pmc: PMC7139355
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Unité de Coodination en Onco-Gériatrie des Pays de Loire
ID : 0
Références
J Clin Oncol. 1998 Jan;16(1):139-44
pubmed: 9440735
Radiother Oncol. 2011 Dec;101(3):460-4
pubmed: 21864924
Eur Urol. 2015 Jul;68(1):53-8
pubmed: 25813688
J Clin Oncol. 2010 Dec 1;28(34):5038-45
pubmed: 21041715
J Clin Oncol. 2012 May 20;30(15):1829-34
pubmed: 22508806
Acta Oncol. 2016 Jul;55(7):807-13
pubmed: 26959297
PLoS One. 2018 Apr 9;13(4):e0194173
pubmed: 29630602
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e325-34
pubmed: 21498008
Eur J Cancer. 2013 Oct;49(15):3176-83
pubmed: 23849828
J Clin Oncol. 2015 Mar 1;33(7):716-22
pubmed: 25559808
Crit Rev Oncol Hematol. 2010 Apr;74(1):66-71
pubmed: 19419885
J Clin Oncol. 2016 Jun 1;34(16):1905-12
pubmed: 27069075
Eur J Cancer. 2003 Mar;39(5):587-94
pubmed: 12628837
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):191-9
pubmed: 21109361
BMC Cancer. 2012 Jul 30;12:324
pubmed: 22846379
Crit Rev Oncol Hematol. 2008 Sep;67(3):243-54
pubmed: 18554922
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):680-9
pubmed: 27055398
Eur Urol. 2013 Oct;64(4):672-9
pubmed: 23587870
J Geriatr Oncol. 2014 Jan;5(1):11-9
pubmed: 24484713
Strahlenther Onkol. 2010 Jan;186(1):46-52
pubmed: 20082188
Clin Oncol (R Coll Radiol). 2017 Sep;29(9):609-616
pubmed: 28592379
PLoS One. 2014 Dec 11;9(12):e115060
pubmed: 25503576
J Clin Oncol. 2013 Apr 10;31(11):1464-70
pubmed: 23460711
J Clin Oncol. 2015 Jun 20;33(18):2021-7
pubmed: 25964245
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Eur J Cancer. 2016 Aug;63:143-53
pubmed: 27318002
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1053-9
pubmed: 19880259
Radiother Oncol. 2010 Oct;97(1):71-5
pubmed: 20307910
Support Care Cancer. 2013 Jun;21(6):1761-71
pubmed: 23455492
Radiat Oncol. 2013 Mar 06;8:53
pubmed: 23510499
J Clin Oncol. 2011 Jan 10;29(2):235-41
pubmed: 21135285